Checkpoint Therapeutics (STU:CZTA) Ending Cash Position : €10.34 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics Ending Cash Position?

Checkpoint Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was €10.34 Mil.

Checkpoint Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 (€1.66 Mil) to Dec. 2023 (€4.52 Mil) and increased from Dec. 2023 (€4.52 Mil) to Mar. 2024 (€10.34 Mil).

Checkpoint Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€48.44 Mil) to Dec. 2022 (€11.39 Mil) and declined from Dec. 2022 (€11.39 Mil) to Dec. 2023 (€4.52 Mil).

Checkpoint Therapeutics Ending Cash Position Historical Data

The historical data trend for Checkpoint Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Ending Cash Position Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

23.47

33.52

48.44

11.39

4.52

Checkpoint Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															4.53	6.85	1.66	4.52	10.34

Checkpoint Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Checkpoint Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	11.066	+	-6.547
	=	4.52

Checkpoint Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.534	+	5.808
	=	10.34

Checkpoint Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics (STU:CZTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (STU:CZTA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CKPT:USA

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Checkpoint Therapeutics (STU:CZTA) Headlines

No Headlines